Matches in SemOpenAlex for { <https://semopenalex.org/work/W4324331341> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W4324331341 endingPage "8661" @default.
- W4324331341 startingPage "8649" @default.
- W4324331341 abstract "The most commonly agents used to treat benign prostatic hyperplasia (BPH) in clinical practice are finasteride and doxazosin employed alone or in combination. Randomized clinical trials have shown that combination therapy with finasteride and doxazosin is superior to finasteride alone or placebo. However, decreased patient compliance may lead to unsatisfactorily therapeutic results. The aim of this study was to assess whether the combined pharmacokinetic profile for both finasteride and doxazosin was not significantly altered when these agents were co-administered, in comparison with their use as single agents. This was a randomized 6 sequences and 3 periods, crossover, comparative study of three medications: finasteride (5 mg), doxazosin (2 mg) (references), and the fixed combination containing 5 mg of finasteride and 2 mg of doxazosin in a single tablet (test). Plasma samples obtained from 30 eligible subjects were analyzed simultaneously for finasteride and doxazosin by HPLC coupled to a LC-MS/MS having cyproterone acetate and terazosin as internal standards. The statistical analysis showed no significant differences for AUC0-72h (finasteride: 245.3±87.8 vs. test: 240.5±93.1 and doxazosin: 183.0±42.9 vs. test: 188.8±45.6 ng.h.mL-1), AUC0-∞ (finasteride: 247.4±92.1 vs. test: 40.47±93.1 and doxazosin: 190.3±44.3 vs. test: 188.8±45.6 ng.h.mL-1), and Cmax (finasteride: 34.2±7.1 vs. test: 29.9±6.2 and doxazosin: 16.3±3.6 vs. test: 14.9±3.3 ng/mL). The mean ratios of AUC0-72h/AUC0-∞ for finasteride and doxazosin were 99.99% and 99.98%, respectively, indicating that the sampling time was adequate for both drugs. In summary, the current pharmacokinetic study demonstrated bioequivalence between the single agents and the corresponding agents in combination and provided further evidence for the lack of pharmacokinetic interaction between finasteride and doxazosin." @default.
- W4324331341 created "2023-03-16" @default.
- W4324331341 creator A5004003974 @default.
- W4324331341 creator A5024114349 @default.
- W4324331341 creator A5057659944 @default.
- W4324331341 creator A5069280137 @default.
- W4324331341 creator A5078674274 @default.
- W4324331341 creator A5082097374 @default.
- W4324331341 date "2023-05-05" @default.
- W4324331341 modified "2023-10-16" @default.
- W4324331341 title "O impacto da COVID-19 no ciclo menstrual: uma perspectiva geral" @default.
- W4324331341 doi "https://doi.org/10.34119/bjhrv6n2-023" @default.
- W4324331341 hasPublicationYear "2023" @default.
- W4324331341 type Work @default.
- W4324331341 citedByCount "0" @default.
- W4324331341 crossrefType "journal-article" @default.
- W4324331341 hasAuthorship W4324331341A5004003974 @default.
- W4324331341 hasAuthorship W4324331341A5024114349 @default.
- W4324331341 hasAuthorship W4324331341A5057659944 @default.
- W4324331341 hasAuthorship W4324331341A5069280137 @default.
- W4324331341 hasAuthorship W4324331341A5078674274 @default.
- W4324331341 hasAuthorship W4324331341A5082097374 @default.
- W4324331341 hasBestOaLocation W43243313411 @default.
- W4324331341 hasConcept C112705442 @default.
- W4324331341 hasConcept C121608353 @default.
- W4324331341 hasConcept C126322002 @default.
- W4324331341 hasConcept C126894567 @default.
- W4324331341 hasConcept C142724271 @default.
- W4324331341 hasConcept C204787440 @default.
- W4324331341 hasConcept C27081682 @default.
- W4324331341 hasConcept C2775874879 @default.
- W4324331341 hasConcept C2776235491 @default.
- W4324331341 hasConcept C2776679619 @default.
- W4324331341 hasConcept C2777562237 @default.
- W4324331341 hasConcept C2777590997 @default.
- W4324331341 hasConcept C71924100 @default.
- W4324331341 hasConcept C84393581 @default.
- W4324331341 hasConcept C98274493 @default.
- W4324331341 hasConceptScore W4324331341C112705442 @default.
- W4324331341 hasConceptScore W4324331341C121608353 @default.
- W4324331341 hasConceptScore W4324331341C126322002 @default.
- W4324331341 hasConceptScore W4324331341C126894567 @default.
- W4324331341 hasConceptScore W4324331341C142724271 @default.
- W4324331341 hasConceptScore W4324331341C204787440 @default.
- W4324331341 hasConceptScore W4324331341C27081682 @default.
- W4324331341 hasConceptScore W4324331341C2775874879 @default.
- W4324331341 hasConceptScore W4324331341C2776235491 @default.
- W4324331341 hasConceptScore W4324331341C2776679619 @default.
- W4324331341 hasConceptScore W4324331341C2777562237 @default.
- W4324331341 hasConceptScore W4324331341C2777590997 @default.
- W4324331341 hasConceptScore W4324331341C71924100 @default.
- W4324331341 hasConceptScore W4324331341C84393581 @default.
- W4324331341 hasConceptScore W4324331341C98274493 @default.
- W4324331341 hasIssue "3" @default.
- W4324331341 hasLocation W43243313411 @default.
- W4324331341 hasOpenAccess W4324331341 @default.
- W4324331341 hasPrimaryLocation W43243313411 @default.
- W4324331341 hasRelatedWork W110432453 @default.
- W4324331341 hasRelatedWork W1966898087 @default.
- W4324331341 hasRelatedWork W2032978819 @default.
- W4324331341 hasRelatedWork W2035004660 @default.
- W4324331341 hasRelatedWork W2049599856 @default.
- W4324331341 hasRelatedWork W2067609693 @default.
- W4324331341 hasRelatedWork W2092719712 @default.
- W4324331341 hasRelatedWork W2178699923 @default.
- W4324331341 hasRelatedWork W2366055913 @default.
- W4324331341 hasRelatedWork W2900207156 @default.
- W4324331341 hasVolume "6" @default.
- W4324331341 isParatext "false" @default.
- W4324331341 isRetracted "false" @default.
- W4324331341 workType "article" @default.